Resumen
The population of survivors with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is rising. The improved prognosis of this etiologic subset is reflected in new staging guidelines as well as ongoing deintensification trials aiming to preserve excellent survival while decreasing treatment-related toxicities. However, as staging criteria and treatment standards evolve in the era of transoral surgery and deintensification, little is known regarding the needs and treatment preferences of patients with HPV-OPSCC. Herein, the current knowledge regarding treatment preferences and priorities, quality of life and concerns among patients with HPV-OPSCC is reviewed.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 2521-2530 |
| Número de páginas | 10 |
| Publicación | Future Oncology |
| Volumen | 14 |
| N.º | 24 |
| DOI | |
| Estado | Published - oct 2018 |
Nota bibliográfica
Publisher Copyright:© 2018 Future Medicine Ltd.
Financiación
M Windon has an NIH grant: 5T32DC000027-29. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
| Financiadores | Número del financiador |
|---|---|
| National Institutes of Health (NIH) | |
| National Institute on Deafness and Other Communication Disorders | T32DC000027 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
